Group 1 - The company Lihexing (SZ 301013) held its 15th meeting of the fourth board of directors on October 23, 2025, to discuss various proposals, including the completion of certain fundraising projects and the permanent allocation of surplus funds to working capital [1] - For the year 2024, the company's revenue composition is as follows: 74.42% from specialized equipment manufacturing and 25.58% from electronic components manufacturing [1] - As of the report date, Lihexing has a market capitalization of 6.7 billion yuan [1] Group 2 - The Chinese innovative pharmaceutical sector has generated $80 billion in overseas licensing deals this year, indicating a robust market for biopharmaceuticals [1] - Despite the hot secondary market for biopharmaceuticals, the primary market is experiencing a cooling in fundraising activities, as noted by investor Lu Gang [1]

Group 1 - The core point of the article highlights that Lihexing (SZ 301013) reported a revenue of approximately 327 million yuan for the first three quarters of 2023, representing a year-on-year decrease of 8.85% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 65.88 million yuan, with basic earnings per share reflecting a loss of 0.28 yuan [1] - As of the report date, Lihexing's market capitalization stands at 6.7 billion yuan [1] Group 2 - The article also mentions that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion US dollars this year, indicating a robust performance in the biopharmaceutical secondary market [1] - A dialogue with Lu Gang, a partner at Chuangdongfang Investment, points out the contrast between the hot secondary market and the cooling fundraising environment in the primary market for the biopharmaceutical sector [1]

国联民生证券承销保荐有限公司关于 深圳市利和兴股份有限公司首次公开发行股票 部分募投项目结项并将节余募集资金永久补充流动资金 及注销募集资金专户的核查意见 国联民生证券承销保荐有限公司（以下简称"国联民生承销保荐"、"保荐机 构"）作为深圳市利和兴股份有限公司（以下简称"利和兴"、"公司"）首次公开 发行股票并在创业板上市的持续督导保荐机构，根据《证券发行上市保荐业务管 理办法》《上市公司募集资金监管规则》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等有关法律法规和规范性文件的要求，国联民生承销保荐对利和兴首次公开发行 股票部分募投项目结项并将节余募集资金永久补充流动资金及注销募集资金专 户进行了核查，发表如下核查意见： 一、募集资金的基本情况 经中国证券监督管理委员会"证监许可[2021]1633 号"《关于同意深圳市利 和兴股份有限公司首次公开发行股票注册的批复》的批复，公司首次向社会公开 发行人民币普通股（A 股）38,957,176 股，每股发行价格 8.72 元，新股发行募集 资金总额为 33,970.66 万元，扣除发行费用 5 ...

关于首次公开发行股票部分募投项目结项 并将节余募集资金永久补充流动资金 证券代码：301013 证券简称：利和兴 公告编号：2025-071 深圳市利和兴股份有限公司 及注销募集资金专户的公告 注：智能装备制造基地项目的"累计已投入募集资金金额"包含了该项目实施期间的闲置募 集资金现金管理利息收入 157.44 万元，该项目已结项。 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市利和兴股份有限公司（以下简称"公司"）于 2025 年 10 月 23 日召开第 四届董事会第十五次会议，审议通过了《关于首次公开发行股票部分募投项目结项 并将节余募集资金永久补充流动资金及注销募集资金专户的议案》，同意公司将首 次公开发行股票募投项目"研发中心建设项目"结项，并将节余募集资金 485.32 万 元（含现金管理取得的理财收益及活期利息收入，具体金额以资金转出当日银行结 算余额为准）永久补充流动资金，用于公司日常经营活动。节余募集资金永久补充 流动资金完成后，公司将按要求注销募集资金专户，公司与保荐机构、开户银行签 署的募集资金专户监管协议随之终止。 根据《深圳证 ...

证券代码：301013 证券简称：利和兴 公告编号：2025-069 深圳市利和兴股份有限公司 第四届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市利和兴股份有限公司（以下简称"公司"）第四届董事会第十五次会议通知 于 2025 年 10 月 14 日以电子邮件等通讯方式发出，于 2025 年 10 月 23 日在公司汇德会 议室以现场结合视频方式召开。会议由公司董事长林宜潘先生主持，应出席董事 7 人， 实际出席董事 7 人，公司全体高级管理人员列席了会议。 本次会议的召集、召开和表决程序符合有关法律、法规和《公司章程》的规定。 二、董事会会议审议情况 （二）审议通过《关于首次公开发行股票部分募投项目结项并将节余募集资金永久 1/2 补充流动资金及注销募集资金专户的议案》 董事会认为：鉴于公司首次公开发行股票募集资金投资项目"研发中心建设项目" 已达到可使用状态，为最大限度地发挥募集资金的使用效益，结合公司实际经营情况， 同意公司将"研发中心建设项目"结项，并将节余募集资金永久补充流动资金，用于与 ...

Revenue and Profitability - The company's revenue for Q3 2025 reached ¥140,794,512.14, representing a 57.21% increase compared to the same period last year[3] - The net profit attributable to shareholders was -¥27,947,754.16, a significant decline of 1,588.42% year-over-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥26,843,729.11, reflecting a decrease of 3,270.87% compared to the previous year[3] - The company's basic and diluted earnings per share were both -¥0.12, reflecting a decrease of 1,600.00% year-over-year[3] - Total operating revenue decreased to ¥327,495,605.22 from ¥359,274,811.92, a decline of approximately 8.5% year-over-year[18] - Net profit for the period was a loss of ¥67,168,117.63, compared to a profit of ¥12,377,672.13 in the previous period, indicating a significant decline[19] - The company reported a basic and diluted earnings per share of -0.28, down from 0.0656 in the previous period[20] Assets and Liabilities - The total assets as of September 30, 2025, amounted to ¥1,540,467,575.84, showing a slight increase of 0.68% from the end of the previous year[3] - Total liabilities increased to ¥777,927,929.83 from ¥690,178,839.35, marking an increase of approximately 12.7%[18] - The total equity attributable to shareholders decreased to ¥767,410,458.27 from ¥843,747,994.57, a decline of about 9.0%[18] - Current assets decreased from RMB 767.532 million to RMB 748.308 million[15] - Cash and cash equivalents decreased from RMB 67.955 million to RMB 40.981 million[15] - Accounts receivable decreased from RMB 421.109 million to RMB 364.637 million[15] - Inventory increased from RMB 219.760 million to RMB 277.965 million[16] - Non-current assets increased from RMB 762.591 million to RMB 792.160 million[16] Cash Flow - The company's cash flow from operating activities was -¥40,901,700.18, a decline of 426.56% compared to the same period last year[8] - The company’s cash inflow from operating activities totaled ¥452,670,446.13, slightly down from ¥457,970,720.33 in the previous period[21] - Cash flow from operating activities showed a net outflow of ¥40,901,700.18, compared to a net inflow of ¥12,524,830.88 in the previous period[21] - Net cash inflow from financing activities improved by 187.90%, reaching ¥50,270,234.44, mainly due to increased cash from borrowings[8] - Net cash inflow from financing activities was $50.27 million, a significant recovery from a net outflow of $57.19 million previously[22] - The total cash and cash equivalents at the end of the period stood at $31.73 million, down from $32.80 million at the end of the previous period[22] - Cash received from borrowings amounted to $225.15 million, compared to $129.35 million in the previous period[22] - Cash paid for debt repayment was $139.12 million, a decrease from $168.74 million in the prior period[22] - The company reported a net cash outflow of $26.34 million for the period, compared to a net outflow of $53.73 million previously[22] Borrowings and Financial Expenses - The company reported a significant increase in short-term borrowings, which rose by 33.61% to ¥271,129,960.45[6] - The financial expenses increased by 37.24% to ¥8,733,100.61, primarily due to higher interest expenses from increased bank borrowings[7] - Short-term borrowings increased from RMB 202.931 million to RMB 271.130 million[16] Shareholder Information - The company has a significant shareholder, Lin Yipan, holding 23.45% of the shares, totaling 54,806,068 shares[11] Research and Development - Research and development expenses were ¥25,592,311.67, down from ¥27,329,314.98, reflecting a decrease of approximately 6.4% year-over-year[18] Other Information - The company received a bid notification from a well-known enterprise in the new energy vehicle industry, with a bid amount of approximately RMB 123 million (excluding tax) [12] - Cumulative orders received under the aforementioned bid amount to approximately RMB 27.573 million (including tax) [12] - The third quarter financial report was not audited[23]

Core Viewpoint - Lihexing (301013) announced that the company and its subsidiaries do not have overdue debts related to guarantees, nor are they involved in any lawsuits concerning guarantees, or any judgments resulting in liability due to guarantees [1] Summary by Relevant Categories - **Debt Status** - The company confirmed that there are no overdue debts associated with guarantees [1] - **Legal Matters** - There are no ongoing lawsuits related to guarantees involving the company or its subsidiaries [1] - **Judicial Outcomes** - The company has not been subject to any judgments that would result in liability due to guarantees [1]

证券代码：301013 证券简称：利和兴 公告编号：2025-068 深圳市利和兴股份有限公司 关于 2025 年度向金融机构申请融资额度提供担保暨关联交易的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、担保暨关联交易概述 深圳市利和兴股份有限公司（以下简称"公司"或"利和兴"）于 2025 年 4 月 24 日召 开第四届董事会第十三次会议和第四届监事会第十一次会议、于 2025 年 5 月 16 日召开 2024 年年度股东大会，分别审议通过了《关于 2025 年度向金融机构申请融资额度及担保额度预计 的议案》和《关于控股股东、实际控制人为公司及子公司 2025 年度向金融机构申请融资额度 提供担保暨关联交易的议案》；同意公司及合并报表范围内的子、孙公司（以下统称"子公 司"）2025 年度预计拟向银行及非银行金融机构（含金融服务机构）申请最高额不超过 15 亿元人民币的综合融资额度，公司及子公司将为融资项下所发生的债务提供包括但不限于保 证、抵押、质押等方式的担保，担保总额度预计不超过 15 亿元人民币；并同意公司控股股东、 实际控制人林 ...

Core Viewpoint - Lihexing (301013) focuses on producing multilayer ceramic capacitors, which are widely used in various sectors including 3C, automotive electronics, 5G communications, medical devices, and renewable energy [1] Group 1: Product Focus - The company's main products are multilayer ceramic capacitors [1] - Lihexing aims to develop high-value-added medium and high-voltage products, as well as high-frequency microwave products in the future [1] Group 2: Market Applications - The products are applicable in multiple fields such as 3C, automotive electronics, 5G communications, medical devices, and photovoltaic inverters [1]

Core Viewpoint - The company, Lihexing (301013), is committed to closely monitoring market changes and aligning with customer demands to seize market opportunities [1] Group 1 - The company will keep a close watch on market dynamics [1] - The company aims to respond to customer needs effectively [1] - The company is focused on capturing market opportunities [1]